Back to discover
Drug

Equol

In clinical development
ClassEstrogen receptor beta agonistEmerging researchEarly-to-mid development

Also known as S-equol, EQUOL, (-)-.

RxNorm1803717ChEMBLCHEMBL198877UNII2T6D2HPX7Q
2
Research papers
3
Active clinical trials
Estrogen receptor beta
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Equol Supplementation for Improving Vascular Function in Postmenopausal Women With CKD

Clinical trial2026-06-02Results expected Q4 2030 · ClinicalTrials.gov

Acute Equol Supplementation and Vascular Function in Postmenopausal Women With and Without CKD

Clinical trial2025-09-30Results expected Q4 2026 · ClinicalTrials.gov

Arterial Stiffness, Cognition and Equol

Clinical trial2025-09-29Results expected Q4 2026 · ClinicalTrials.gov

From Gut to Hormones: Unraveling the Role of Gut Microbiota in (Phyto)Estrogen Modulation in Health and Disease.

Research2024-02-11Molecular nutrition & food research

A Pre-surgical Clinical Trial of Therapy With S-equol in Women With Triple Negative Breast Cancer.

Clinical trial2020-06-30Completed · ClinicalTrials.gov

Equol: A Bacterial Metabolite from The Daidzein Isoflavone and Its Presumed Beneficial Health Effects.

Research2019-09-16Nutrients

Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS 131 (S Equol) on Benign Prostatic Hyperplasia

Clinical trial2017-05-19Results posted · ClinicalTrials.gov

Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS-131 (S-equol) on Vasomotor Symptoms in Menopausal Patients

Clinical trial2014-04-08Results posted · ClinicalTrials.gov

Randomized, Double-Blind, Rising Multiple Dose Study of S-Equol in Normal Volunteers

Clinical trial2009-04-01Completed · ClinicalTrials.gov

Randomized, Double-Blind, Single Rising Dose Study of S-equol in Normal Volunteers

Clinical trial2008-12-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Equol
Aliases & brands
S-equolEQUOL, (-)-
RxNorm CUI
1803717
ChEMBL ID
CHEMBL198877
UNII
2T6D2HPX7Q
Primary mechanism
Estrogen receptor beta agonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Estrogen receptor beta
ESR2 · Q92731
AGONISTEstrogen receptor beta agonist

Clinical trials

8 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
8
registered trials across all phases
LATEST COMPLETION 2020
3
Active studies
2
Recruiting
5
Completed
PHASE DISTRIBUTIONn = 8
Early Phase 11Phase 12Phase 25

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Pre-surgical Clinical Trial of Therapy With S-equol in Women With Triple Negative Breast Cancer.

CompletedPH IThe University of Texas Health Science Center at San Antonion=392020

Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS 131 (S Equol) on Benign Prostatic Hyperplasia

CompletedPH IIAusio Pharmaceuticals, LLCn=1162016

Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS-131 (S-equol) on Vasomotor Symptoms in Menopausal Patients

CompletedPH IIAusio Pharmaceuticals, LLCn=1692011

Randomized, Double-Blind, Rising Multiple Dose Study of S-Equol in Normal Volunteers

CompletedPH IAusio Pharmaceuticals, LLCn=412009

Randomized, Double-Blind, Single Rising Dose Study of S-equol in Normal Volunteers

CompletedPH IAusio Pharmaceuticals, LLCn=602008

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20192024
Major research themes3
Gastrointestinal Microbiome2Breast Neoplasms1Diet1
Journals, researchers & institutions
Top journals
  • Molecular nutrition & food research1
  • Nutrients1
Leading researchers
  • Dua A1
  • Duyar-Ayerdi S1
  • Flórez AB1
  • Kumar R1
  • Kumari N1
  • Kumari R1
  • Mayo B1
  • Ojesina AI1
Leading institutions
free-text, unnormalised
  • College of Commerce1
  • Instituto de Investigación Sanitaria del Principado de Asturias (ISPA)1
  • Instituto de Productos Lácteos de Asturias (IPLA)1
  • Magadh University1
  • Medical College of Wisconsin1
  • Shivaji College1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Estrogens

Studied across the same disease area as Equol in the shared literature.

1 shared disease1 shared paper
Daidzein

Frequently co-studied with Equol in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials